Gapping up 

KTCC +28.4%, AZPN +11%, FTNT +9.6%, NVS +3%, WFT +2.7%, DB +2.6%, BRCM +2.6%, SI +2.2%, BCS +1.8%, MT +1.8%, SLV +1.8%, ACE +1.7%,

WHR +8.6%, STX +7.4%, MTW +5.6%, ALV +5.6%, TMO +3.9%,  AOL +3.6%, BEAV +1.1%, NAV +1.1%, RBS +4.5%, NBG +2.7%, STD +2.7%,  BAC +1%,

MT +2.3%, SLV +1.8%, CLF +1.7%, AA +1.6%, GOLD +1.2%, GLD +0.2%, WLT +2.7%, PCX +2.6%, WFT +2.2%, RIG +2.2%, JRCC +1.7%, SD +0.5%, MCP +4.9%,

MDVN +17.3%,  SGMO +7% ,  DNDN +4.6%, RIO +0.9%,  MGM +2.3% ,

Gapping down

PLT -14.7%, JDAS -9.2%, AMZN -8.7%, UBNT -8.6%, BDSI -8.2%, MPW -5.8%, STLY -4%, SLGN -3.8%, HLIT -1.4%, KEYN -1.1%,  UIS -6.5%, CHRW -5.9%, MPW -5.8%,

TUP -1.7%, GGC -5.2%,  BDSI -8.2%, KWK -7.8%, TROW -2.2%,

In Play 

On the Wires 

FB is the target of some 22 + patent infringement cases…. 

Full report

Full report

For the full year they swung into a net income of $183 million.

No “quasi monopoly” in derivatives trading was the final straw to block the deal…

H/T @darrenrovell

_______________

(via)

Facebook is expected to file to raise US$5bn in a preliminary IPO prospectus on Wednesday morning, which while less than anticipated could be increased to ultimate investor demand, according to sources close to the deal.

The smaller deal size reflects a decision to start with a conservative base before deciding whether to increase.

The social networking site has opted to hire five bookrunners, featuring Morgan Stanley in the coveted lead left role.Goldman Sachs, Bank of America Merrill Lynch, Barclays Capital and JP Morgan round out the initial list of bookrunners on the deal, though the syndicate could also grow, sources indicated.

The filing timetable appears to establish a framework for Facebook to finalise the IPO process by May, pending a smooth registration process with the SEC.

Investment banking sources note the company has been unusually guarded about the process for selecting banks involved in the underwriting syndicate, but Morgan Stanley’s market leading position in Internet IPOs has given it an upper hand in securing the leading role.

Morgan Stanley’s selection implies that Facebook took account of Goldman Sachs’ handling of a private placement last year, though some have also pointed to Facebook’s desire to distance itself from the bank.

With final pricing of Facebook shares unlikely to be settled for at least three months, it is still unclear what valuation the company is targeting on the IPO.

Recent trading in Facebook stock on private exchanges has pointed to a US$80bn-plus valuation.

AMZN is off $19 bones on the report…

A novel idea to improving customer service.

Predatory is the only word for this behavior.

Nice try…

Nothing to see here folks…a fine will be paid eventually for business as usual.

Fourth quarter profits were down significantly as the world continues to change….

Post Holdings Inc. (POST-W) (POST-W US) will replace Comstock Resources Inc. (CRK) in the S&P MidCap 400 Index, and Comstock will take THQ Inc. (THQ)’s (THQI US) place in the S&P SmallCap 600 Index, after trading closes on Feb. 3, S&P said.

The change is being made because Ralcorp Holdings Inc. (RAH) is spinning off Post in a transaction expected to be completed on or about Feb. 3, S&P said in a statement.

Align Technology Inc. (ALGN) : The maker of a teeth- straightening product forecast first-quarter profit excluding some items of no more 21 cents a share, below the average analyst estimate of 22 cents in a Bloomberg survey.

Archer-Daniels-Midland Co. (ADM) fell 3.1 percent to $28.80. The world’s largest grain processor posted a second- quarter profit that missed analysts’ estimates after oilseed earnings fell and corn costs rose.

Biogen Idec Inc. (BIIB) retreated 3.1 percent to $113. The world’s largest maker of multiple sclerosis medicines said it sees earnings in 2012 of no more than $6.20 a share, excluding some items, missing the average analyst estimate of $6.31.

Eli Lilly & Co. (LLY US) advanced 1.2 percent to $39.70. The pharmaceutical company whose schizophrenia drug Zyprexa lost patent protection in October said fourth-quarter profit excluding some items was 87 cents a share, beating the 81-cent average of 17 analyst estimates compiled by Bloomberg.

Hologic Inc. (HOLX) : The Bedford, Massachusetts-based maker of X-ray systems raised its 2012 profit forecast to as much as $1.38 a share, more than the average analyst estimate of $1.36 a share.

Mattel Inc. (MAT) gained 1.2 percent to $29.87. The maker of Barbie dolls reported fourth-quarter profit of $1.07 a share, excluding some items, beating the $1 average analyst estimate.

Parexel International Corp. (PRXL) : The tester of experimental medicines for drugmakers forecast third-quarter earnings of as much as 32 cents a share excluding some items, above the average analyst estimate of 30 cents a share, according to a Bloomberg survey.

Pfizer Inc. (PFE) increased 1.3 percent to $21.85. The world’s largest drugmaker beat analysts’ earnings estimates as the company’s non-pharmaceutical divisions helped make up for sales losses from generic competition to its best-seller Lipitor. The company lowered its 2012 forecast.

RadioShack Corp. (RSH) plunged 25 percent to $7.70. The consumer-electronics retailer suspended share repurchases and reported preliminary fourth-quarter earnings that trailed analysts’ estimates. Earnings fell to 11 cents to 13 cents a share last quarter. Analysts projected 37 cents, the average of 19 estimates compiled by Bloomberg. RadioShack cited “underperformance” in the Sprint Nextel Corp. (S) postpaid wireless business.

Rex Energy Corp. (REXX) : The oil and gas company with operations in the Illinois and Appalachian basin announced plans for a public offering of 7 million ordinary shares. Additional stock may dilute the value of existing shares.

Source